Joo Young Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joo Young Kim has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Jun Chang
Graduate School of Pharmaceutical Sciences, Ewha Womans University, Republic of Korea
14 shared publications - Jung-Won Park
Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
4 shared publications - Eun Young Choi
Department of Biomedical Sciences, Seoul National University, Seoul, Republic of Korea
3 shared publications - Hye Sun Lee
Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
3 shared publications Ji-Min Ju
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea
3 shared publicationsYoungjoo Choi
Laboratory Science Division, International Vaccine Institute, Seoul, South Korea
3 shared publications
Latest Publications
- Open Access
- 9 July 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (24) , e2500963
Dissolving Microneedle for Maintaining the Integrity of HPV Virus‐Like Particles Enabling Durable Sterile Protection Across Various Mucosal Tissues
Human papillomavirus (HPV) vaccines have substantially reduced cervical cancer and other HPV‐related diseases in high‐income countries, with male vaccination addressing transmission as well as head and neck cancers. However, in low‐ and middle‐income countries, widespread vaccination efforts are hindered by considerable costs, insufficient medical staff, and challenges in maintaining vaccine stability. Conventional microneedle vaccine production often compromises the structural integrity of virus‐like particles (VLPs), thereby reducing their effectiveness. To address this challenge, a dissolving microneedle platform is developed that preserves VLP stability for over six months. Administration of this vaccine platform to buccal tissue enables effective antigen delivery, inducing T follicular helper (Tfh) cell differentiation, germinal center formation, and the production of high‐titer neutralizing antibodies. Buccal application also conferred sterilizing immunity in both buccal and vaginal tissues. Moreover, the vaccine induced durable immune memory, with memory B cells and plasma cells persisting in buccal tissue and bone marrow for six months. This innovation addresses critical barriers in resource‐limited regions by enhancing VLP stability and accessibility. Furthermore, the platform's applicability extends to other vaccines requiring structural integrity for efficacy, representing a transformative approach to global immunization efforts.
- 9 July 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (24) , e2500963
Open AccessDissolving Microneedle for Maintaining the Integrity of HPV Virus‐Like Particles Enabling Durable Sterile Protection Across Various Mucosal Tissues
Human papillomavirus (HPV) vaccines have substantially reduced cervical cancer and other HPV‐related diseases in high‐income countries, with male vaccination addressing transmission as well as head and neck cancers. However, in low‐ and middle‐income countries, widespread vaccination efforts are hindered by considerable costs, insufficient medical staff, and challenges in maintaining vaccine stability. Conventional microneedle vaccine production often compromises the structural integrity of virus‐like particles (VLPs), thereby reducing their effectiveness. To address this challenge, a dissolving microneedle platform is developed that preserves VLP stability for over six months. Administration of this vaccine platform to buccal tissue enables effective antigen delivery, inducing T follicular helper (Tfh) cell differentiation, germinal center formation, and the production of high‐titer neutralizing antibodies. Buccal application also conferred sterilizing immunity in both buccal and vaginal tissues. Moreover, the vaccine induced durable immune memory, with memory B cells and plasma cells persisting in buccal tissue and bone marrow for six months. This innovation addresses critical barriers in resource‐limited regions by enhancing VLP stability and accessibility. Furthermore, the platform's applicability extends to other vaccines requiring structural integrity for efficacy, representing a transformative approach to global immunization efforts.
- Open Access
- 28 March 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 567
Sublingual Immunization With an RSV G Glycoprotein Fragment Primes IL-17-Mediated Immunopathology Upon Respiratory Syncytial Virus Infection
Respiratory syncytial virus (RSV) is the leading cause of serious respiratory tract disease but there is no licensed RSV vaccine. Immunopathological mechanisms have long been suspected as operating in the development of severe RSV disease and have hampered the development of safe and effective vaccines. Here, we show that unlike intranasal immunization, sublingual immunization with RSV glycoprotein fragment containing the central conserved region (Gcf) primes the host for severe disease upon RSV challenge. This increased pathology does not require replication by the challenge virus and is associated with massive infiltration of inflammatory cells, extensive cell death, and excessive mucus production in the airway and lungs. This exacerbated RSV disease primed by sublingual Gcf immunization is distinct from the immunopathology by G-expressing vaccinia virus or formalin-inactivated RSV, and preceded by prominent IL-17 production. IL-17 deficiency abolished the enhanced disease. Our results suggest a novel mechanism of RSV vaccine-induced immunopathology by IL-17, and highlights the importance of vaccination site.
- 28 March 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 567
Open AccessSublingual Immunization With an RSV G Glycoprotein Fragment Primes IL-17-Mediated Immunopathology Upon Respiratory Syncytial Virus Infection
Respiratory syncytial virus (RSV) is the leading cause of serious respiratory tract disease but there is no licensed RSV vaccine. Immunopathological mechanisms have long been suspected as operating in the development of severe RSV disease and have hampered the development of safe and effective vaccines. Here, we show that unlike intranasal immunization, sublingual immunization with RSV glycoprotein fragment containing the central conserved region (Gcf) primes the host for severe disease upon RSV challenge. This increased pathology does not require replication by the challenge virus and is associated with massive infiltration of inflammatory cells, extensive cell death, and excessive mucus production in the airway and lungs. This exacerbated RSV disease primed by sublingual Gcf immunization is distinct from the immunopathology by G-expressing vaccinia virus or formalin-inactivated RSV, and preceded by prominent IL-17 production. IL-17 deficiency abolished the enhanced disease. Our results suggest a novel mechanism of RSV vaccine-induced immunopathology by IL-17, and highlights the importance of vaccination site.
- Open Access
- 21 March 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-9
Combined Effect of Secondhand Smoking and Alcohol Drinking on Risk of Persistent Human Papillomavirus Infection
Tobacco smoking is established as a cofactor of human papillomavirus (HPV) for cervical cancer risk. However, the role of secondhand smoking in cervical carcinogenesis is controversial. We aimed to assess the association between secondhand smoking and high risk- (HR-) HPV persistence, a pivotal event in development of cervical cancer. In total, 9,846 women who underwent health-screening examinations from 2002 to 2011 at the National Cancer Center, Korea, were included. Secondhand smoking was defined as being exposed to secondhand smoke at home or in the workplace. Multivariate logistic regression analysis was used to estimate the odds ratios (OR) and 95% confidence intervals (CIs) for risks of HR-HPV infection at baseline (N, 9,846, negative vs. positive), 1-year persistence (n, 1,237, 1-year negative vs. 1-year persistence), and 2-year persistence (n, 481, 2-year negative vs. 2-year persistence). Active smoking, secondhand smoking, and secondhand smoking in nonactive smokers had no association with these risks. Among alcohol drinkers, secondhand smoking in nonactive smokers had higher risks of HR-HPV infection at baseline (OR = 1.25, 95% CI = 1.05–1.48, p for multiplicative interaction = 0.003), 1-year persistence (1.75, 1.14–2.68, 0.004), and 2-year persistence (2.96, 1.42–6.15, 0.006), when compared to HR-HPV negative, 1-year negative, and 2-year negative categories, respectively. However, among nonalcohol drinkers, there was no association between smoking or secondhand smoking status and these risks. These findings suggest that women exposed to secondhand smoking at home or in the workplace might be at high risk of HR-HPV persistence when it is combined with alcohol drinking, even though neither active smoking nor secondhand smoking independently affects the risk.
- 21 March 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-9
Open AccessCombined Effect of Secondhand Smoking and Alcohol Drinking on Risk of Persistent Human Papillomavirus Infection
Tobacco smoking is established as a cofactor of human papillomavirus (HPV) for cervical cancer risk. However, the role of secondhand smoking in cervical carcinogenesis is controversial. We aimed to assess the association between secondhand smoking and high risk- (HR-) HPV persistence, a pivotal event in development of cervical cancer. In total, 9,846 women who underwent health-screening examinations from 2002 to 2011 at the National Cancer Center, Korea, were included. Secondhand smoking was defined as being exposed to secondhand smoke at home or in the workplace. Multivariate logistic regression analysis was used to estimate the odds ratios (OR) and 95% confidence intervals (CIs) for risks of HR-HPV infection at baseline (N, 9,846, negative vs. positive), 1-year persistence (n, 1,237, 1-year negative vs. 1-year persistence), and 2-year persistence (n, 481, 2-year negative vs. 2-year persistence). Active smoking, secondhand smoking, and secondhand smoking in nonactive smokers had no association with these risks. Among alcohol drinkers, secondhand smoking in nonactive smokers had higher risks of HR-HPV infection at baseline (OR = 1.25, 95% CI = 1.05–1.48, p for multiplicative interaction = 0.003), 1-year persistence (1.75, 1.14–2.68, 0.004), and 2-year persistence (2.96, 1.42–6.15, 0.006), when compared to HR-HPV negative, 1-year negative, and 2-year negative categories, respectively. However, among nonalcohol drinkers, there was no association between smoking or secondhand smoking status and these risks. These findings suggest that women exposed to secondhand smoking at home or in the workplace might be at high risk of HR-HPV persistence when it is combined with alcohol drinking, even though neither active smoking nor secondhand smoking independently affects the risk.
- 1 March 2019
- Published by Elsevier in Antiviral Research
- Vol. 163, 19-28
Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus
- 1 March 2019
- Published by Elsevier in Antiviral Research
- Vol. 163, 19-28
Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus
- 1 January 2019
- Published by Elsevier in Experimental Gerontology
- Vol. 115, 148-154
Voluntary exercise reverses immune aging induced by oxidative stress in aging mice
- 1 January 2019
- Published by Elsevier in Experimental Gerontology
- Vol. 115, 148-154
Voluntary exercise reverses immune aging induced by oxidative stress in aging mice
- 1 October 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 151 (1) , 39-45
Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial
- 1 October 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 151 (1) , 39-45
Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial
- Open Access
- 24 August 2018
- Published by Korean Society of Exercise Rehabilitation in Journal of Exercise Rehabilitation
- Vol. 14 (4) , 660-665
The effects of combined aerobic and resistance training on inflammatory markers in obese men
It is important to treat obesity and the related noncommunicable diseases. The main objective of this study is the effect of different training types on inflammatory and immune markers in obesity. Seventeen obese men with body mass index (BMI)≥26 kg/m2 were randomly divided into two groups: aerobic training group (AT; n=9) and combined aerobic and resistance training group (CT; n=8). Body composition (weight, BMI, %body fat), factors of physical performance (one-repetition maximum [1RM], maximal oxygen uptake [VO2max]), inflammatory markers (interleukin-6, tumor necrosis factor-alpha [TNF-α]), immune markers (leukocyte, natural killer cell) were analyzed before and after 8-week training. Body composition (weight, BMI, and %body fat) was significantly reduced after training in both the AT and CT groups (P2max of all training groups was increased and 1RM of CT group was partially improved. In particular, the inflammatory marker, TNF-α was significantly reduced (P<0.05) and the change was correlated with %body fat in the posttraining CT group. In this study, we found that combined training for 8 weeks improved physical fitness, body composition, and inflammation. It is suggested that restoring obesity through combined training of aerobic and resistance exercise is related to changes in serum TNF-α levels.
- 24 August 2018
- Published by Korean Society of Exercise Rehabilitation in Journal of Exercise Rehabilitation
- Vol. 14 (4) , 660-665
Open AccessThe effects of combined aerobic and resistance training on inflammatory markers in obese men
It is important to treat obesity and the related noncommunicable diseases. The main objective of this study is the effect of different training types on inflammatory and immune markers in obesity. Seventeen obese men with body mass index (BMI)≥26 kg/m2 were randomly divided into two groups: aerobic training group (AT; n=9) and combined aerobic and resistance training group (CT; n=8). Body composition (weight, BMI, %body fat), factors of physical performance (one-repetition maximum [1RM], maximal oxygen uptake [VO2max]), inflammatory markers (interleukin-6, tumor necrosis factor-alpha [TNF-α]), immune markers (leukocyte, natural killer cell) were analyzed before and after 8-week training. Body composition (weight, BMI, and %body fat) was significantly reduced after training in both the AT and CT groups (P2max of all training groups was increased and 1RM of CT group was partially improved. In particular, the inflammatory marker, TNF-α was significantly reduced (P<0.05) and the change was correlated with %body fat in the posttraining CT group. In this study, we found that combined training for 8 weeks improved physical fitness, body composition, and inflammation. It is suggested that restoring obesity through combined training of aerobic and resistance exercise is related to changes in serum TNF-α levels.
- Open Access
- 1 February 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 116
Pan-Influenza A Protection by Prime–Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model
Influenza virus infections continually pose a major public health threat with seasonal epidemics and sporadic pandemics worldwide. While currently licensed influenza vaccines provide only strain-specific protection, antigenic drift and shift occasionally render the viruses resistant to the host immune responses, which highlight the need for a vaccine that provides broad protection against multiple subtypes. In this study, we suggest a vaccination strategy using cold-adapted, live attenuated influenza vaccines (CAIVs) to provide a broad, potent, and safe cross-protection covering antigenically distinct hemagglutinin (HA) groups 1 and 2 influenza viruses. Using a mouse model, we tested different prime–boost combinations of CAIVs for their ability to induce humoral and T-cell responses, and protective efficacy against H1 and H5 (HA group 1) as well as H3 and H7 (HA group 2) influenza viruses. Notably, even in the absence of antibody-mediated neutralizing activity or HA inhibitory activity in vitro, CAIVs provided a potent protection against heterologous and heterosubtypic lethal challenges in vivo. Heterologous combination of prime (H1)–boost (H5) vaccine strains showed the most potent cross-protection efficacy. In vivo depletion experiments demonstrated not only that T cells and natural killer cells contributed to the cross-protection, but also the involvement of antibody-dependent mechanisms for the cross-protection. Vaccination-induced antibodies did not enhance the infectivity of heterologous viruses, and prime vaccination did not interfere with neutralizing antibody generation by the boost vaccination, allaying vaccine safety concerns associated with heterogeneity between the vaccines and challenge strains. Our data show that CAIV-based strategy can serve as a simple but powerful option for developing a “truly” universal influenza vaccine providing pan-influenza A protection, which has not been achieved yet by other vaccine strategies. The promising results of potency, breadth, and safety demonstrated in the mouse model support further studies in higher animal models for clinical relevance.
- 1 February 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 116
Open AccessPan-Influenza A Protection by Prime–Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model
Influenza virus infections continually pose a major public health threat with seasonal epidemics and sporadic pandemics worldwide. While currently licensed influenza vaccines provide only strain-specific protection, antigenic drift and shift occasionally render the viruses resistant to the host immune responses, which highlight the need for a vaccine that provides broad protection against multiple subtypes. In this study, we suggest a vaccination strategy using cold-adapted, live attenuated influenza vaccines (CAIVs) to provide a broad, potent, and safe cross-protection covering antigenically distinct hemagglutinin (HA) groups 1 and 2 influenza viruses. Using a mouse model, we tested different prime–boost combinations of CAIVs for their ability to induce humoral and T-cell responses, and protective efficacy against H1 and H5 (HA group 1) as well as H3 and H7 (HA group 2) influenza viruses. Notably, even in the absence of antibody-mediated neutralizing activity or HA inhibitory activity in vitro, CAIVs provided a potent protection against heterologous and heterosubtypic lethal challenges in vivo. Heterologous combination of prime (H1)–boost (H5) vaccine strains showed the most potent cross-protection efficacy. In vivo depletion experiments demonstrated not only that T cells and natural killer cells contributed to the cross-protection, but also the involvement of antibody-dependent mechanisms for the cross-protection. Vaccination-induced antibodies did not enhance the infectivity of heterologous viruses, and prime vaccination did not interfere with neutralizing antibody generation by the boost vaccination, allaying vaccine safety concerns associated with heterogeneity between the vaccines and challenge strains. Our data show that CAIV-based strategy can serve as a simple but powerful option for developing a “truly” universal influenza vaccine providing pan-influenza A protection, which has not been achieved yet by other vaccine strategies. The promising results of potency, breadth, and safety demonstrated in the mouse model support further studies in higher animal models for clinical relevance.
- Open Access
- 15 January 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 225
Escape from thymic deletion and anti-leukemic effects of T cells specific for hematopoietic cell-restricted antigen
Whether hematopoietic cell-restricted distribution of antigens affects the degree of thymic negative selection has not been investigated in detail. Here, we show that T cells specific for hematopoietic cell-restricted antigens (HRA) are not completely deleted in the thymus, using the mouse minor histocompatibility antigen H60, the expression of which is restricted to hematopoietic cells. As a result, low avidity T cells escape from thymic deletion. This incomplete thymic deletion occurs to the T cells developing de novo in the thymus of H60-positive recipients in H60-mismatched bone marrow transplantation (BMT). H60-specific thymic deletion escapee CD8+T cells exhibit effector differentiation potentials in the periphery and contribute to graft-versus-leukemia effects in the recipients of H60-mismatched BMT, regressing H60+hematological tumors. These results provide information essential for understanding thymic negative selection and developing a strategy to treat hematological tumors.
- 15 January 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 225
Open AccessEscape from thymic deletion and anti-leukemic effects of T cells specific for hematopoietic cell-restricted antigen
Whether hematopoietic cell-restricted distribution of antigens affects the degree of thymic negative selection has not been investigated in detail. Here, we show that T cells specific for hematopoietic cell-restricted antigens (HRA) are not completely deleted in the thymus, using the mouse minor histocompatibility antigen H60, the expression of which is restricted to hematopoietic cells. As a result, low avidity T cells escape from thymic deletion. This incomplete thymic deletion occurs to the T cells developing de novo in the thymus of H60-positive recipients in H60-mismatched bone marrow transplantation (BMT). H60-specific thymic deletion escapee CD8+T cells exhibit effector differentiation potentials in the periphery and contribute to graft-versus-leukemia effects in the recipients of H60-mismatched BMT, regressing H60+hematological tumors. These results provide information essential for understanding thymic negative selection and developing a strategy to treat hematological tumors.